Get the Stockscreener App
3.17
1.60%
0.05
After Hours:
3.12
-0.05
-1.58%
Briacell Therapeutics Corp stock is traded at $3.17, with a volume of 162.41K.
It is up +1.60% in the last 24 hours and down -27.13% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$3.12
Open:
$3.11
24h Volume:
162.41K
Relative Volume:
0.14
Market Cap:
$23.17M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-3.5618
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-7.31%
1M Performance:
-27.13%
6M Performance:
-64.80%
1Y Performance:
-90.52%
1-Day Range:
$3.04
$3.22
1-Week Range:
$3.04
$3.57
52-Week Range:
$3.04
$33.64
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
3.17 | 23.17M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
(BCT) Risk-Controlled Trading Report (BCT:CA) - news.stocktradersdaily.com
(BCT) Trading Advice (BCT:CA) - news.stocktradersdaily.com
(BCT) Investment Performance Report (BCT:CA) - news.stocktradersdaily.com
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty - PR Newswire
BriaCell (BCTX) Highlights Promising Biomarkers in Metastatic Br - GuruFocus
BriaCell Therapeutics Corp. - Baystreet.ca
Stocks In Play: BriaCell Therapeutics Corp. - Barchart.com
How To Trade (BCT) (BCT:CA) - news.stocktradersdaily.com
BriaCell’s Phase 3 Data Shows Promise for Metastatic Breast Cancer Treatment - TipRanks
BriaCell (BCTX) Highlights Promising Biomarkers in Metastatic Breast Cancer Study | BCTX Stock News - GuruFocus
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Posit - GuruFocus
Buy This Dividend-Paying Tech Stock to Play the Low-Cost China AI Story - The Globe and Mail
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: - GlobeNewswire
Game-Changing Cancer Biomarkers: BriaCell Phase 3 Data Shows How to Predict Treatment Success - Stock Titan
Occidental’s Hidden Gem: How OxyChem Could Boost Profits - The Globe and Mail
BriaCell (BCTX) Reveals Promising Phase 2 and Preclinical Data a - GuruFocus
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering | BCTX Stock News - GuruFocus
BriaCell Therapeutics closes $13.8M public offering - MSN
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering - The Manila Times
Briacell Therapeutics Announces Closing Of $13.8 Million Public Offering - marketscreener.com
BriaCell Secures $13.8M Funding Boost: New Capital to Accelerate Cancer Immunotherapy Development - Stock Titan
Vitalhub Corp. - Baystreet.ca
BriaCell Presents Benchmark Beating Survival and Clinical Benefi - GuruFocus
BriaCell’s Breakthrough in Cancer Immunotherapy at AACR 2025 - TipRanks
BriaCell Presents Benchmark Beating Survival and Clinical - GlobeNewswire
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development - The Manila Times
BriaCell's Breast Cancer Immunotherapy Shows Breakthrough 17.3-Month Survival in Latest Trial Data - Stock Titan
BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail's Busy Cheering Clinical Milestone - MSN
Briacell Therapeutics Corp. - MENAFN.com
Littelfuse Earnings: What To Look For From LFUS - The Globe and Mail
(BCT) Trading Performance and Risk Management (BCT:CA) - news.stocktradersdaily.com
BriaCell (BCTX) Prices Public Offering of Units to Raise $13.8 M - GuruFocus
Increased Share Offering for XYZ Corp (XYZ) Priced Below Market - GuruFocus
BriaCell Therapeutics (BCTX) Prices $13.8 Million Public Offerin - GuruFocus
BriaCell Therapeutics to Raise $13.8 Million in Public Offering; Shares Fall - marketscreener.com
BriaCell's Stock Dips Following Public Offering Announcement - Finimize
BriaCell Therapeutics (BCTX) Prices $13.8 Million Public Offering - GuruFocus
BriaCell Therapeutics Down 17% In US Premarket As Prices US$13.8 Million Public Offering - marketscreener.com
BriaCell Therapeutics announces pricing of $13.8 million public offering - MSN
(BCT) Trading Report (BCT:CA) - news.stocktradersdaily.com
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering | BCTX Stock News - GuruFocus
BriaCell Stock Dips After-Hours On Pricing $13.8M Public Offering, But Retail’s Busy Cheering Clinical Milestone - Investing.com India
BriaCell Therapeutics Announces $13.8 Million Public Offering - TipRanks
BriaCell Raises $13.8M: Strong Institutional Demand Drives Full Exercise of Underwriter Option - Stock Titan
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering - The Manila Times
Briacell Therapeutics Says Units Priced At $4.50 Each For Gross Proceeds Of $13.8 Million - marketscreener.com
BriaCell reports complete lung metastasis resolution in breast cancer study By Investing.com - Investing.com South Africa
BriaCell's Bria-OTS shows sustained success against breast cancer | 2025-04-24 | Investing News - Stockhouse
BriaCell confirms 100% resolution of lung metastasis with Bria-OTS - TipRanks
Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher - Benzinga
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):